David Wilding, MD
Internal Medicine · Brigham City, UTNPI 1740391226
Payments from drug & device makers
Across 336 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$767
- Johnson & Johnson$548
- AstraZeneca$381
- Amarin Pharma, Inc.$232
- Novartis$219
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,714100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 134 | $1,971 |
| Amgen | 41 | $767 |
| Johnson & Johnson | 38 | $548 |
| AstraZeneca | 10 | $381 |
| Amarin Pharma, Inc. | 16 | $232 |
| Novartis | 12 | $219 |
| Pfizer | 8 | $136 |
| Insulet Corporation | 1 | $135 |
| Abbott | 6 | $124 |
| Astellas Pharma US Inc | 5 | $98 |
| Nestle Healthcare Nutrition Inc. | 6 | $94 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Phathom Pharmaceuticals, Inc. | 1 | $74 |
| Biohaven Pharmaceuticals, Inc. | 4 | $70 |
| Novo Nordisk | 5 | $68 |
| Lilly USA, LLC | 5 | $66 |
| Organon | 5 | $59 |
| Merck | 4 | $56 |
| Boston Scientific | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| GSK | 2 | $40 |
| Medtronic | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 3 | $36 |
| Dexcom, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Edwards Lifesciences | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 2 | $22 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,714 in reported general payments places this provider in the 85th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $123,375 |
| XareltoRivaroxaban | 78 | $88,315 |
| FarxigaDapagliflozin Propanediol | 79 | $71,082 |
| OzempicSemaglutide | 49 | $56,808 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 50 | $38,732 |
| JanuviaSitagliptin Phosphate | 56 | $38,036 |
| JardianceEmpagliflozin | 37 | $34,619 |
| TrulicityDulaglutide | 21 | $30,200 |
| MyrbetriqMirabegron | 27 | $24,354 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 106 | $17,226 |
| MounjaroTirzepatide | 14 | $13,436 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $13,434 |
| LinzessLinaclotide | 20 | $12,485 |
| Omeprazole | 353 | $7,151 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $4,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $136 | $123,375134 claims |
| Johnson & JohnsonXarelto | $548 | $88,31578 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $381 | $84,516100 claims |
| Novo NordiskOzempic | $68 | $56,80849 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $66 | $43,63635 claims |
| MerckJanuvia | $56 | $38,03656 claims |
| Boehringer IngelheimJardiance | $28 | $34,61937 claims |
| Astellas Pharma US IncMyrbetriq | $98 | $24,35427 claims |
| AbbVieLinzess, Synthroid | $1,971 | $14,91344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Brigham City
- Ahad SabetSalt Lake City$34.5M
- Barbara RizzardiSandy$27.8M
- Willard DereSalt Lake City$4.7M
- Joseph WoolleySaint George$3.6M
- Justin MansfieldOgden$3.1M
- Michael KillpackSandy$2M
- Cuper Martinez SantibanezWest Valley City$1M
- Joshua OaksBountiful$973K
- Brandon WebbSalt Lake City$544K
- Yong Hui AhnSlc$474K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.